The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer

Current Oncology Reports

Volumn 13, Issue 4, 2011, Pages 280-289

  West, Howard ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Anti angiogenesis; Bevacizumab; Cetuximab; EGFR; Erlotinib; Evolving role of targeted therapy in early stage and locally advanced non small cell lung cancer; Gefitinib; Immunotherapy locally advanced NSCLC; L BLP 25 vaccine; Lung cancer; MAGE A3; MUC 1; NSCLC; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; L BLP 25; MELANOMA ANTIGEN 3 VACCINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG FATALITY; EARLY CANCER; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; RASH; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 80051670952     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0181-0     Document Type: Review

References (34)

1. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf, accessed 3/22/2011.
2. International Adjuvant Lung Cancer Trial Collaborative Group 2004 Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 351 360 10.1056/NEJMoa031644 (Pubitemid 38101630)
3. T Winton R Livingston D Johnson, et al. 2005 Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2589 2597 15972865 10.1056/NEJMoa043623 1:CAS:528:DC%2BD2MXls1Wqurg%3D (Pubitemid 41007845)
4. J-Y Douillard R Rosell M De Lena, et al. 2006 Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial Lancet Oncol 7 719 727 16945766 10.1016/S1470-2045(06)70804-X 1:CAS:528:DC%2BD28Xptlyku7c%3D (Pubitemid 44283661)
5. N Thatcher A Chang P Parikh, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 16257339 10.1016/S0140-6736(05)67625-8 1:CAS:528:DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
6. W Pao J Chmielecki 2010 Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 10 760 774 20966921 10.1038/nrc2947 1:CAS:528:DC%2BC3cXhtlWlsrrN
7. MH Cohen JR Johnson Y-F Chen, et al. 2005 FDA drug approval summary: Erlotinib (Tarceva) Tablets Oncologist 7 461 466 10.1634/theoncologist.10-7-461 (Pubitemid 41266326)
8. FA Shepherd JR Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
9. M Maemondo A Inoue K Kobayashi, et al. 2010 Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380 2388 20573926 10.1056/NEJMoa0909530 1:CAS:528:DC%2BC3cXot1Gjt7Y%3D
10. T Mitsudomi S Morita Y Yatabe, et al. 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer horbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial Lancet Oncol 11 121 128 20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
11. N Ready P Janne J Bogart, et al. 2010 Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer And Leukemia Group B (CALEB) (sic) 30106, a CALGB-Stratified Phase II Trial J Thor Oncol 5 1382 1390 10.1097/JTO. 0b013e3181eba657
12. K Kelly K Chansky LE Gaspar, et al. 2008 Phase III trial of gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer. SWOG S0023 J Clin Oncol 20 2450 2456 10.1200/JCO.2007.14.4824 The SWOG 0023 trial produced the extremely surprising result of demonstrating a significant detrimental effect for maintenance gefitinib after chemotherapy and concurrent radiation followed by consolidation docetaxel. Though still essentially unexplained, this finding underscores the importance of testing molecular markers in prospective clinical trials rather than presuming that favorable results in the setting of advanced NSCLC will definitely translate to other clinical settings.
13. J Rigas M Carey 2009 Rubin M Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation (D0410, NCT00153803) J Thor Oncol 4 S371 10.1097/JTO.0b013e31819846e4
14. TS Mok Y-L Wu S Thongprasert, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK The IPASS trial by Mok and colleagues demonstrated that there are fundamental differences in outcomes with EGFR TKIs versus chemotherapy that are predicated overwhelmingly on molecular predictors rather than clinical variables. In fact, the clinical predictors of more favorable outcome with EGFR TKIs appear to be related to their correlation with molecular markers such as EGFR mutation, and those people with the same clinical and histologic features but an absence of an EGFR mutation were clearly better served by chemotherapy than an EGFR TKI as first-line therapy for advanced NSCLC.
15. YY Janjigian BJ Park MF Zakowski, et al. 2011 Impact on disease-free survival of adjuvant erlotinib or gefitinib in pateints with resected lung adenocarcinomas that harbor EGFR mutations J Thor Oncol 6 569 575 10.1097/JTO.0b013e318202bffe
16. GD Goss I Lorimer MS Tsao, et al. 2010 A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 J Clin Oncol 28 18s (LBA7005) 10.1200/JCO.2009.22.9427 Similar to the SWOG 0023 trial, the BR.19 study demonstrated very counterintuitive results of a strong suggestion of a detrimental effect for adjuvant gefitinib, and even more surprising was the observation that patients with an activating EGFR mutation had a trend toward an even more unfavorable result in terms of PFS and OS compared to recipients of placebo in this prematurely terminated trial.
17. http://www.clinicaltrials.gov/ct2/show/NCT00373425?term= RADIANT+erlotinib&rank=1, accessed 3/22/11.
18. http://www.clinicaltrials.gov/ct2/show/NCT00567359?term= EGFR+mutation+sequist&rank=5, accessed 3/22/11.
19. http://www.clinicaltrials.gov/ct2/show/NCT00775385?term= IFCT-0801&rank=1, accessed 3/22/11.
20. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 16957145 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
21. R Pirker JR Pereira A Szczesna, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open label randomized phase III trial Lancet 373 1525 1531 19410716 10.1016/S0140-6736(09) 60569-9 1:CAS:528:DC%2BD1MXltlaqurs%3D
22. Govindan R, Bogart J, Wang X, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol. 2009;27:A#7505.
23. Blumenschein GR, Paulus R, Curran WJ, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol. 2008;26:A#7516.
24. http://www.clinicaltrials.gov/ct2/show/NCT00533949?term= RTOG+0617&rank=1, accessed 3/22/11.
25. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
26. http://www.clinicaltrials.gov/ct2/show/NCT00324805?term= ECOG+1505&rank=1, accessed 3/22/11.
27. DH Johnson L Fehrenbacher WF Novotny, et al. 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191 15169807 10.1200/JCO.2004.11.022 1:CAS:528:DC%2BD2cXpsVWltrg%3D (Pubitemid 41095154)
28. DR Spigel JD Hainsworth DA Yardley, et al. 2010 Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 43 48 19901100 10.1200/JCO.2009.24.7353 1:CAS:528:DC%2BC3cXhtF2ku7k%3D This report led to a highly publicized campaign to raise awareness of the potential danger of integrating bevacizumab into concurrent treatment with chest irradiation, as this practice appears to be associated with an unacceptably high risk of developing a tracheoesophageal fistula. Fortunately, this was detected based on its occurrence in several patients in a pair of prospective clinical trials and argues against combining targeted therapies with other treatment modalities outside of a clinical setting.
29. B Goodgame N Veeramachaneni A Patterson, et al. 2008 Tracheo-esophageal fistula with bevacizumab after mediastinal radiation J Thor Oncol 3 1080 1081 10.1097/JTO.0b013e3181858eba
30. http://www.clinicaltrials.gov/ct2/show/NCT00334815?term= swog+0533&rank=1, accessed 3/22/11.
31. Vansteenkiste J, Zielinski M, Dahabre J, et al. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-postiive, completely resected, non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24:A#7019.
32. http://www.clinicaltrials.gov/ct2/show/NCT00480025?term=MAGRIT&rank= 1, accessed 3/22/11.
33. C Butts N Murray A Maksymuik, et al. 2005 Randomized phase IIB trial of BLP25 liposomal vaccine in stage IIIB and IV non-small cell lung cancer J Clin Oncol 23 6674 6681 16170175 10.1200/JCO.2005.13.011 1:CAS:528:DC%2BD2MXhtFWqsLbF (Pubitemid 46190262)
34. http://www.clinicaltrials.gov/ct2/show/NCT01015443?term= stimuvax&rank=4, accessed 3/22/11.